22nd April 2019- Neurelis, Inc. issued an announcement, which is summarized as follows：
Neurelis, Inc. announced today that the company has completed the buildout of its senior management team to support the anticipated launch of its lead product, VALTOCO (diazepam nasal spray). Neurelis President and CEO Craig Chambliss stated: “Over the past two years, we have been incredibly fortunate to add these talented executives to our team at this pivotal time. The unparalleled level of expertise, specifically in the outpatient seizure emergency market, positions Neurelis to significantly benefit the epilepsy community in the very near term.”VALTOCO currently under U.S. FDA review, Neurelis is preparing for the commercial launch of VALTOCO.
The following management additions to the Neurelis team:
George Stuart, Chief Financial Officer：has 29 years of finance and accounting experience, the majority of which have been spent within the specialty pharmaceutical and biotechnology industry.
Chuck DeWildt, Chief Commercial Officer：has served in leadership roles in Sales, Marketing, and Market Access in the pharmaceutical and biotechnology industry for more than 25 years.
Adrian Rabinowicz, M.D., Senior Vice President of Clinical Development & Medical Affairs：joined Neurelis in 2018 and is a board-certified neurologist with over 20 years of experience in global pharmaceutical and biotechnology companies.
Thomas Liquard, Senior Vice President, Corporate Development：brings more than 15 years of organizational, corporate development, and commercial development leadership experience in the life sciences industry to Neurelis.
Steve Jenner, Vice President of Marketing & Operations：has more than 20 years of experience in the pharmaceutical and biotechnology industry with specific experience in the neurology, pain, glaucoma, and dermatology markets. Steve joined the Neurelis team in early 2019.
The original website link：